Natco logs record net in FY25, headwinds for U.S. unit a concern
Natco Pharma estimates a possible dip in revenue by 20% and profit by as much 30% in FY26 on account of geopolitical uncertainties and pricing pressure in its core product portfolio in U.S. and due to increased research and development (R&D) experises On the back of a strong cash position of more than ₹3,000 crore as of March 31, 2025, it is preparing for headwinds coming from U.S. business during FY26. The Hyderabad-based ge-neric drugmaker said this announcing a consolidated net profit for FY25 at 1,883.4 crore and a total revenue of ₹4,784 crore, both highest thus far. While net profit was a rise of 36% compared with *1,388.3 crore in 2023-24, total revenue was 16% higher from ₹4,126.9 crore a year earlier. The guidance for the current fiscal comes after vice-chairman and CEO Rajeev Nannapaneni in Fe-bruary this year told inves-tors, in the backdrop of U.S. threatening high ta-riffs on pharma imports, about the need for a front-end manufacturing in the U.S. "That's the only way you can go forward. Ap-pears to be the only solu-tion," he had said. For Q4, Natco posted 5% higher net profit at ₹406 crore on an almost 16% rise in revene to ₹1,287.3 crore.
Comments
Post a Comment